Standard Biotools Inc. · NASDAQ:LAB
Standard Biotools — Investor Presentation (January 2023)
23 slides from Standard Biotools's investor presentation, Jan 9, 2023
Slide 1: Standard BioTools Corporate Presentation January 2023
Standard BioTools Corporate Presentation January 2023
Slide 2: Legal information: Forward-Looking Statements
Legal information 2 Forward - Looking Statements This presentation and the accompanying oral presentation contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the expected advantages of and dema
Slide 3: Standard BioTools mission and vision
Standard BioTools mission and vision 3 Vision to be a top - quartile life science research tools company in 3 – 5 years, becoming the established standard in our customers’ workflows Cutting - edge tools that enable scientists to make breakthroughs faster and more efficiently Focus on standardized w
Slide 4: Investment highlights
Investment highlights 4 Platform Create a diversified, innovation - focused life science tools company serving the pharma research markets Strategic M&A Execute on highly strategic M&A across a broad target universe leveraging existing infrastructure Top - Grade Team World class team of seasoned ope
Slide 5: The gap
The gap 5 Standard BioTools Elements of Success Early - Stage LST Company Struggles ▪ Poor product - market fit and demand generation ▪ Lack of roadmap and application development Customer - centric marketing, product management and development organization Marketing and Product Development Global,
Slide 6: The approach
The approach 6 ▪ Complementary and de - risked technology acquisitions ▪ Proprietary deal flow to expand portfolio into high - growth segments ▪ Growth ▪ Cost ▪ Performance ▪ Quality ▪ Safety ▪ Delivery Drive Growth Create Value Deliver Profitability ACQUIRE LEVERAGE IMPROVE ▪ Seasoned management te
Slide 7: Management team with shared experience
Management team with shared experience 7 Alex Kim Chief Operating Officer Jeremy Davis Chief Commercial Officer Mona Abou - Sayed SVP, SBS Anders Davas SVP, Global Operations Michael Egholm, PhD Chief Executive Officer Vikram Jog Chief Financial Officer Betsy Jensen Chief Human Resources Officer Dav
Slide 8: Strategic Priorities
Strategic Priorities ` ` 1. Revenue Growth 2. Improve Operating Discipline 3. Strategic Capital Allocation Early Results ▪ Sequential revenue growth of core product services business ▪ Phased restructuring program underway resulting in expected $33M in O pEx improvement ▪ Deep M&A funnel with opport
Slide 9: Portfolio of high-parameter spatial and multi-omic technologies
Portfolio of high - parameter spatial and multi - omic technologies ▪ High flexibility ▪ Rapid panel design ▪ 9,216 reactions in < 1 hour ▪ Ideal for precious samples and expensive probes Maxpar ® Assays & Kits CyTOF ® XT Flow Cytometry X9 γ Real - Time PCR System Integrated Fluidic Circuit 96x96 |
Slide 10: Proteomics
PROTEOMICS
Slide 11: The age of the immune system
The age of the immune system 11 0 20 40 60 Number of markers Information content PROTEOMICS IMMUNE PROFILING IS THE KEY TO UNLOCKING MANY THERAPIES Basic inventory of the immune system requires 30+ markers Real insight grows exponentially with every additional marker
Slide 12: The problem with fluorescence
The problem with fluorescence PROTEOMICS Cyclical staining Stain Image Strip • Panel design takes months (Flow) • Nonspecific binding (Imaging) • Difficult workflows Other considerations Spectral overlap What color did I see? Fluorescence is challenged by autofluorescence and spectral overlap Can ov
Slide 13: The solution: Mass Cytometry
The solution I Mass Cytometry Labeling with isotopes gives digital readout Enables 50+ markers in a single scan • No autofluorescence • No spectral overlap • Simple and quick panel design 13 Mass Cytometry – metal tags identified by mass spectrometry – no overlap NEXT - GEN LABELING TECHNOLOGY PROTE
Slide 14: The proof: we win in the marketplace of results
The proof I We win in the marketplace of results 14 96% Of more than 1,850 publications with 20 or more protein markers 96% use mass cytometry!* PROTEOMICS Lab Others 96% All others * Estimated based on latest available information γ
Slide 15: Mass Cytometry enabling single-cell biology
Mass Cytometry enabling single - cell biology 15 Translating high - parameter single cell and tissue imaging into real world, actionable results PROTEOMICS Flow Cytometry – CyTOF • Single - cell analysis • 13 samples per run • 50+ markers per sample Imaging Mass Cytometry Ρ : – Hyperion Ρ Imaging Sy
Slide 16: Genomics
GENOMICS
Slide 17: Genomics a powerful microfluidic solution for target markets
Genomics a powerful microfluidic solution for target markets 17 GENOMICS Proprietary integrated fluidic circuit (IFC) IFC Formats 96x96 | 48x48 | 192x24 • Rapid (singleplex) panel design • Easy swapping of probes • 9,216 reactions in < 1 hour • Ideal for precious samples and expensive probes Proprie
Slide 18: Financials
FINANCIALS
Slide 19: Financials
Financials Cash/Equivalents Year End 2022: $165 million Targets: • Gross margin: 65% - 68% by end of 2023 • Free Cash Flow: breakeven by end of 2024 19
Slide 20: Strategic priorities
Strategic priorities 1. Revenue Growth • Accelerate growth in Proteomics and focus Genomics toward profitable growth • Compete in growing markets where we have, or could have, a competitive advantage • Focus on servicing more customers in translational and clinical research 2. Improve Operating Disc
Slide 21: Translating strategy into action
Translating strategy into action Corporate • Phased restructuring • Cut expected $30M+ from OpEx • Reduced headcount 15% • Reduced SSF footprint 25% • Reduced SG&A expenses • Results in 2,000 bp improvement in EBIT 21 WHAT WE’VE DONE SO FAR Proteomics/Mass Cytometry • Hyperion XTi launch April ‘23 •
Slide 22: Investment highlights
Investment highlights 22 Platform Create a diversified, innovation - focused life science tools company serving the pharma research markets Strategic M&A Execute on highly strategic M&A across a broad target universe leveraging existing infrastructure Top Grade Team World class team of seasoned oper
Slide 23: Thank You
Unleashing tools to accelerate breakthroughs in human health γ Thank You
Standard Biotools — Investor Presentation (January 2023) on 6ix